FRLN - Freeline Therapeutics GAAP EPS of -$1.50 beats by $0.28
2023-04-04 07:02:46 ET
- Freeline Therapeutics press release ( NASDAQ: FRLN ): FY GAAP EPS of -$1.50 beats by $0.28 .
- As of December 31, 2022, unrestricted cash and cash equivalents were $47.3 million, compared to $117.7 million as of December 31, 2021.
For further details see:
Freeline Therapeutics GAAP EPS of -$1.50 beats by $0.28